Accueil > Actualité
Actualite financiere : Actualite bourse

Merck: acquires Themis

( - Merck & Co has announced that it has reached a final agreement to acquire Themis, an unlisted company specializing in vaccines and immune modulating therapies for infectious diseases and cancer.
The terms of the deal were not specified.

The pharmaceutical company explained that this acquisition should accelerate the development of the Themis experimental vaccine for Covid-19, a vaccine in a preclinical development phase, for which clinical studies should start later in 2020.

In connection with this acquisition, Merck has signed a memorandum of understanding with Institut Pasteur and the CEPI reflecting their commitment to treating the Covid-19 pandemic by offering a vaccine at an affordable price worldwide.

Copyright (c) 2020 All rights reserved.




Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.
Indices et cours différés d’au moins 15 mn | Cotations boursières fournies par ABC Bourse.